Key Points {#FPar1}
==========

Pharmacovigilance analysis of the US FDA Adverse Event Reporting System (FAERS) database provided a signal of association between subacute cutaneous lupus erythematosus and proton pump inhibitors.Statistical analysis and published case reports confirmed the association.Proton pump inhibitors should be discontinued if subacute cutaneous lupus erythematosus symptoms occur.

Introduction {#Sec1}
============

The rate of autoimmune disorders is increasing exponentially in the Western world. In the USA, the prevalence of autoimmune disease has risen from 3 % in the 1960s to 9 % in 2009 \[[@CR1]\]. One of the autoimmune diseases is lupus erythematosus, in which a hyperactive immune system attacks its own tissue cells. Subacute cutaneous lupus erythematosus (SCLE) is a distinct subset of cutaneous lupus erythematosus and presents clinically with non-scarring, erythematous, annular polycyclic or papulosquamous cutaneous eruptions in sun-exposed areas \[[@CR2]\]. While SCLE can be idiopathic or drug induced, they are generally immunologically, histopathologically, and clinically indistinguishable. Thiazides, terbinafine, calcium channel blockers, angiotensin-converting enzyme inhibitors (ACEIs), tumor necrosis factor (TNF)-α inhibitors, and chemotherapeutic agents have all been implicated as suspected or probable causes of drug-induced SCLE. Proton pump inhibitors (PPIs) have also been associated with and may induce SCLE.

The US FDA does not recognize SCLE as a PPI-associated adverse event, and FDA-approved prescribing information for PPIs does not include SCLE as an associated adverse event. In this article, we analyze passive pharmacovigilance signals for PPI-associated SCLE and support our findings with published case reports and case--control studies. PPIs as a class work by inhibiting gastric acid secretion in the gastric lumen. They inhibit the K+/H+ ATPase pump in the lining of gastric parietal cells \[[@CR3]\]. This causes a reduction in acid secretion because hydrogen ions are unable to be transported to the gastric surface. PPIs are used to treat conditions such as dyspepsia and gastroesophageal reflux disease (GERD). This group of inhibitors comprises some of the World Health Organization (WHO) "World's essential medications" such as omeprazole, pantoprazole, and lansoprazole.

Methods {#Sec2}
=======

Data Collection {#Sec3}
---------------

The FDA Adverse Event Reporting System (FAERS) database collects spontaneous reports of adverse events and medication errors involving human drugs and therapeutic biological products. The information is publically available as computerized quarterly data reports on the FAERS website \[[@CR4]\]. Adverse event and medication error reports are submitted to the FDA by drug manufacturers, healthcare professionals (e.g., physicians, pharmacists, and nurses), and consumers (e.g., patients, family members, and lawyers). The original Adverse Event Reporting System (AERS) was designed in 1969 to support the FDA's post-marketing safety surveillance program for drug and therapeutic biologic products. It was replaced by FAERS on 10 September 2012, and the database now contains over 9 million reports of adverse events from 1969 to the present day. Since the last major revision, in 1997, reporting has markedly increased. The quarterly data files, available in ASCII or SGML formats, include demographic and administrative information; drug, reaction, and patient outcome information from the reports; and information on the source of the reports \[[@CR4]\].

The adverse events data for the present analysis were obtained from the FAERS website for the period 1 July 2013 to 30 June 2015. The data tables "Demographics," "Drugs," "Indications," "Outcomes, Reactions," "Report Source," and "Therapy" were downloaded and imported into SQL Server (Microsoft SQL Server 2015); we then combined the files using primary key and foreign keys. The resulting tables were cleaned and duplicates removed. The data were queried using SQL queries.

Adverse Event and Exposure Drug {#Sec4}
-------------------------------

We investigated the adverse event "subacute cutaneous lupus erythematosus" and the drug class PPIs as being associated with SCLE. The PPI class was defined as comprising any of the following drugs: esomeprazole, dexlansoprazole, omeprazole, lansoprazole, pantoprazole, or rabeprazole, singularly or in combination.

Analysis {#Sec5}
--------

Disproportionality analysis can be used to identify statistical associations between products and events in their respective safety report databases. Such analysis compares the observed count for a product--event combination with an "expected" count. Unexpectedly high reporting associations "signal" that there may be a causal association between the particular adverse event and the product. This analysis can also identify increased reporting rates for low frequency events.

We used disproportionality analysis to quantify pharmacovigilance signals in FAERS to provide a picture of the drug-related risk. The association between the adverse event and the drugs of interest was evaluated using the Chi squared (*χ*^2^) value with Yates correction, with values \>4 considered statistically significant. We also calculated measurements of disproportionality (observed--expected ratios): relative reporting ratio (RRR), proportional reporting ratio (PRR), and reporting odds ratio (ROR), and their 95 % confidence intervals. Generally, the higher the ratios, the more likely the association between drug(s) and adverse event(s). According to the criteria of Evans et al. \[[@CR5]\], if (number of events ≥3, *χ*^2^ ≥ 4, and PRR ≥ 2), the combination of drug(s) and adverse event(s) is considered "likely" to be an adverse reaction.

Results {#Sec6}
=======

Analysis Results {#Sec7}
----------------

A total of 220 cases listing SCLE as an adverse event were reported during the 2-year period (third quarter of 2013 to second quarter of 2015) with the use of any drug. Of these, 190 were reported by healthcare professionals and four by consumers; none were reported by lawyers. The source for the remaining 26 was missing from the database. Table [1](#Tab1){ref-type="table"} summarizes the major drug classes reported to have been associated with SCLE during the period, and Table [2](#Tab2){ref-type="table"} presents the demographics of the patients for whom the adverse events were reported.Table 1The top ten drug classes associated with subacute cutaneous lupus erythematosus reported in the US FDA Adverse Event Reporting System database between 1 July 2013 and 30 June 2015, stratified by drug classS. no.Drug classReported SCLE cases (*n*)1PPI1202Statins343Corticosteroids274Thiazide diuretics255ACEI/ARB226Thyroid medications207Aspirin168Beta blocker159Benzodiazepine1510Stool softener13*ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *PPI* proton pump inhibitor, *SCLE* subacute cutaneous lupus erythematosusTable 2Demographics of patients with subacute cutaneous lupus erythematosus reported in the US FDA Adverse Event Reporting System database between 1 July 2013 and 30 June 2015CharacteristicTotal (*n* = 220)Associated with PPI (*n* = 120)Associated with other drugs (*n* = 100)Sex^a^ Male26 (11.8)9 (7.5)17 (17.0) Female170 (77.3)97 (80.8)73 (73.0) Missing24 (10.9)14 (11.7)10 (10.0)Age (years) \<2510 (4.5)10 (8.3)0 (0) ≥25 and \<5050 (22.7)25 (20.8)25 (25.0) ≥50 and \<7071 (32.3)44 (36.7)27 (27.0) ≥70 and \<8656 (25.5)19 (15.8)37 (37.0) Missing33 (15.0)22 (18.3)11 (11.0) Mortality7 (3.2)5 (4.2)2 (2.0)Data are presented as *n* (%)*PPI* proton pump inhibitor^a^Fisher's exact test (PPI and 'other drugs' vs. 'male' and 'female': *p* = 0.0269 \[one tailed\])

The query in the SQL data tables identified that more than half (120) of the 220 SCLE adverse events were associated with PPIs. Of the 120 cases associated with PPIs, 95 were reported by healthcare professions and two by consumers; none were reported by lawyers. The source for the remaining 24 was missing from the database. Of the 120 adverse events, 95 % were coded as serious, with death reported as an outcome in 4.2 %. PPIs were identified as the "primary suspect" drug in all 120 adverse events. Table [3](#Tab3){ref-type="table"} presents a 2 × 2 table of the queried results; *χ*^2^ with Yates correction was 1874.74.Table 32 × 2 Contingency tables for reported proton pump inhibitor-associated subacute cutaneous lupus erythematosusSexPPIsAll other drugsTotalAll SCLE120100220 All other AEs56,6041,732,0981,788,702 Total AEs56,7241,732,1981,788,922 *χ* ^2^ with Yates correction: 1874.74Female SCLE9773170 All other AEs31,546966,585998,131 Total AEs31,643966,658998,301 *χ* ^2^ with Yates correction: 1591.27Male SCLE91726 All other AEs22,810597,071619,881 Total AEs22,819597,088619,907 *χ* ^2^ with Yates correction: 61.72*AE* adverse event, *PPI* proton pump inhibitor, *SCLE* subacute cutaneous lupus erythematosus

Table [4](#Tab4){ref-type="table"} presents the disproportionality ratios. A comparison of the results of the passive pharmacovigilance analysis using FAERS data (*n* = 120; *χ*^2^ = 1874.74, PRR = 36.64 \[95 % CI 28.10--47.77\]) and Evans et al. \[[@CR5]\] criteria (*n* ≥ 3, *χ*^2^ ≥ 4, PRR ≥2) indicates that SCLE is statistically significantly associated with PPIs.Table 4Disproportionality analysis results for reported proton pump inhibitor-associated subacute cutaneous lupus erythematosusSexMeasureRatio (95 % CI)AllProportional reporting ratio36.64 (28.10--47.77)Relative odds ratio36.72 (28.16--47.89)Relative reporting ratio17.20 (13.77--21.48)FemaleProportional reporting ratio40.59 (29.97--54.99)Relative odds ratio40.71 (30.05--55.17)Relative reporting ratio18.00 (14.03--23.09)MaleProportional reporting ratio13.85 (6.18--31.07)Relative odds ratio13.86 (6.18--31.09)Relative reporting ratio9.40 (4.41--20.07)*CI* confidence interval

Of the 120 PPI-associated SCLE cases, 68 reports indicate the drug was withdrawn after the event; no report indicated a drug reduction, and only one report indicated that drug dose remained unchanged. The other 51 cases reported no action or "unknown." Of the 120 PPI-induced SCLE cases, only nine were reported to have been followed longitudinally. All nine were reported to have reoccurred on re-administration of the drug.

We subsequently stratified the data by sex and obtained the corresponding disproportionality results. Table [3](#Tab3){ref-type="table"} presents a 2 × 2 table of the queried stratified results, and Table [4](#Tab4){ref-type="table"} presents the corresponding disproportionality ratios. The stratified results indicate that SCLE is statistically significantly associated with PPIs as an adverse event in women (*n* = 97; *χ*^2^ = 1591.27; PRR = 40.59 \[95 % CI 29.97--54.99\]). A significant association is also seen in men, but to a lesser extent (*n* = 9; *χ*^2^ = 61.72; PRR = 13.85 \[95 % CI 6.18--31.07\]).

When SCLE occurs and the PPI is discontinued but the patient still requires acid-suppression medication, one option is to prescribe H2 receptor antagonists such as cimetidine, famotidine, nizatidine, or ranitidine. We could not identify via the FAERS data whether an H2 receptor antagonist was started after a PPI was discontinued, and the ensuing outcome of that switch on SCLE. However, we did analyze FAERS data during the same time period to check for any independent association between SCLE and H2 receptor antagonists (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}). The results indicate that SCLE is also significantly associated with H2 receptor antagonists, but to a much smaller extent (*n* = 5; *χ*^2^ = 7.29; PRR = 3.74 \[95 % CI 1.54--9.07\]) than with PPIs.Table 52 × 2 Contingency table for reported H2 receptor antagonist-associated subacute cutaneous lupus erythematosusH2 receptor antagonistsAll other drugsTotalSCLE5215220All other AEs11,0571,777,6451,788,702Total AEs11,0621,777,8601,788,922*χ* ^2^ with Yates correction: 7.29*AE* adverse event, *SCLE* subacute cutaneous lupus erythematosusTable 6Disproportionality analysis results for reported H2 receptor antagonist-associated subacute cutaneous lupus erythematosusMeasureRatio (95 % CI)Proportional reporting ratio3.74 (1.54--9.07)Relative odds ratio3.74 (1.54--9.08)Relative reporting ratio3.68 (1.52--8.92)H2 receptor antagonist-associated SCLE cases = 7/220*CI* confidence interval

Supporting Literature {#Sec8}
---------------------

We conducted a brief review of the literature relating to PPI-associated SCLE. We searched PubMed for published studies (2000--2015) \[[@CR6]\] to discern the validity of passive pharmacovigilance. The literature studies reviewed are broadly classified as clinical case reports, retrospective studies, and case--control studies.

### Clinical Case Reports {#Sec9}

We identified 22 clinical case reports from 21 patients (Table [7](#Tab7){ref-type="table"}). The mean patient age was 58.33 years (range 30--85), and 20 of the 21 patients were female. One patient was pregnant when she experienced the adverse reaction. The presence of antinuclear antibodies, including anti-Ro/SSA antibodies and anti-La/SSB antibodies, in blood serum can be used to diagnose autoimmune disorders. Antinuclear antibodies, positive anti-Ro/SSA antibodies, and positive anti-La/SSB antibodies were found in 90, 90, and 36 % of tested patients at the time of the rash, respectively. The incubation period was in the range of 3 days to 5 months (mean 5 weeks), and the resolution period was in the range of a few days to 4 months (mean 4.33 weeks) after the discontinuation of the PPI. SCLE recurred in two patients with PPI re-challenge and resolved after drug cessation. Two patients in whom the PPI was not stopped had active SCLE up to their deaths (death reported as due to other causes).Table 7Summary of the 21 case reports of proton pump inhibitor-induced subacute cutaneous lupus erythematosus reported in the literature (2000--2015) as identified in PubMed\#Study (year)Age (years), sex, race, countryDrug (dose)Latency (drug intro to SCLE)Area of onsetClinical findings/relevant serologyMedication after discontinuation of PPITime to remission after accused PPI discontinuation1Reich and Maj (2012) \[[@CR15]\]57, F, CaucasianLansoprazole3 monthsTrunk, face, both extremities, V-neck areaFatigue, leucopoenia, decreased C3 complement component, leukocyturia, erythrocyturia, ANA+, SSA+Prednisone 0.5 mg/kg/day and ranitidine 150 mg bid helped in remission4 weeks2Toms-Whittle et al. (2011) \[[@CR16]\]85, F, UKOmeprazole4 monthsUpper back, upper arms, cheeksESR = 45 mm in 1 h, ANA+, SSA+, SSB−, histone+, dsDNA+Hydroxychloroquine (200 mg daily) exacerbated rash4 weeks3Toms-Whittle et al. (2011) \[[@CR16]\]78, F, UKOmeprazole3 monthsChest, upper back, arms, face, abdomen, legsANA+, SSA+, SSB+, dsDNA−, ESR = 12 mm12 weeks4Correia et al. (2001) \[[@CR17]\]73, F, Caucasian, PortugalPantoprazole (40 mg/day)2 weeksErythematous maculopapular eruption: face, scalp, ears, anterior V of chestSSA+, rheumatoid factor+Oral histamines and prednisolone1 month5Bracke et al. (2005) \[[@CR18]\]69, F, Caucasian, BelgiumLansoprazole3 monthsTrunk, extremities, face, neckESR elevated, ANA+, SSA+, histone--No effect of oral prednisolone (32 mg/day) for 1 month and hydroxyzine for 2 months3 weeks6Bracke et al. (2005) \[[@CR18]\]63, F, BelgiumLansoprazole5 monthsTrunk, extremitiesANA+ (speckled), SSA+, rheumatoid factor +1 month; no reoccurrence in next 5 years.7Jones et al. (2015) \[[@CR19]\]73, F, African-American, USAPantoprazoleForehead, neck, back, upper and lower extremitiesANA+ (speckled), SSA+, SSB−, dsDNA−, histone−Amlodipine stopped (was provided with pantoprazole initially); amlodipine restarted after 1 month1 month8Hung et al. (2015) \[[@CR20]\]60, F, UKOmeprazoleTrunk, thighs, backPrevious history of SCLE, ANA+, SSA+Prednisolone and mycophenolate mofetil4 months9Almebayadh et al. (2013) \[[@CR21]\]30, M (originally from island of Martinique)Pantoprazole1 monthTrunk, lower limbsANA+ (speckled), SSA+, SSB+, histone−8 weeks (relapsed when pantoprazole accidently re-challenged)10Almebayadh et al. (2013) \[[@CR21]\]31, F (originally from Canada)Esomeprazole (20 mg/day) (no other treatment)7 weeksTrunk, scalp, facePregnant, ANA+ (speckled), SSA+, SSB−, histone−After discontinuing PPI, topical steroids and hydroxychloroquine 400 mg daily were started. After 2 weeks, oral steroid added (0.25 mg/kg/day)4 weeks11Almebayadh et al. (2013) \[[@CR21]\]57, F (originally from island of Martinique)OmeprazoleFew weeksTrunk, upper and lower limbsANA+, SSA+, anti-SM, anti-RNP antibodiesNot mentioned12Wee et al. (2012) \[[@CR22]\]73, F, UKOmeprazole (and naproxen) started 1 week before 1st flareFirst flare: 1 weekTrunk, limbsPre-existing idiopathic SCLE, ANA+, SSA+, dsDNA−Omeprazole and naproxen stopped by patient 5 days after the onset of flare2 monthsOmeprazole (and naproxen) re-started 2 weeks before 2nd flare2 weeksOmeprazole stopped; naproxen continued5 weeks13Alcántara-González et al. (2011) \[[@CR23]\]74, F, SpainEsomeprazole3 weeksErythematosus papules on back; lesser extent on chest, thighs, armsANA+, SSA+, SSB+8 weeks14Dam and Bygum (2008) \[[@CR8]\]F, 63, DenmarkPantoprazole3 days (short latency as re-exposure)Chest, trunkANA−, SSA+, SSB−, histone−4 weeks15Dam and Bygum (2008) \[[@CR8]\]M, 57, DenmarkLansoprazole4 weeksTrunk, upper and lower extremitiesANA+, SSA+, dsDNA+, histone−, RF+Treated with hydroxychloroquine, topical steroids; oral prednisolone 30 mg daily; azathioprine 100 mg daily added. Lansoprazole continued as not suspectedDied 2 years later due to other cause with active skin disease and ongoing lansoprazole treatment16Dam and Bygum (2008) \[[@CR8]\]F, 61, DenmarkLansoprazole3 weeksANA+, SSA+, SSB−, dsDNA−, histone−, RF+12 weeks17Dam and Bygum (2008) \[[@CR8]\]F, 50, DenmarkOmeprazole7 weeksANA+, dsDNA+, histone−4 weeks18Dam and Bygum (2008) \[[@CR8]\]F, 51, DenmarkPantoprazole4--8 weeksANA+, SSA−, SSB−, dsDNA−, RF+Active SCLE up to death; death due to other cause19Mankia et al. (2010) \[[@CR24]\]60, F, UKOmeprazole4 monthsArms, trunk, legsANA+, SSA+, SSB−, histone−Betamethasone1 month20Drago et al. (2015) \[[@CR25]\]48, F, ItalyLansoprazole2 monthsTrunk, limbsANA−, SSA+Replaced by alginate and bicarbonate sodiumFew days21Panting et al. (2009) \[[@CR26]\]61, F, UKLansoprazole4 weeksPhoto-exposed areas: shoulders, chest, upper arms, legsTired, ANA+, SSA+, SSB−8 weeks without topical steroids; relapse on re-administration after 5 months that resolved on drug cessation*ANA* antinuclear antibodies, *bid* twice daily, *dsDNA* antibodies to double-stranded DNA, *ESR* erythrocyte sedimentation rate, *histone* antihistone antibodies, *SSA* anti-Ro/SSA antibodies, *SSB* anti-La/SSB antibodies

### Chart Review {#Sec10}

Sandholdt et al. \[[@CR7]\] reported a retrospective medical chart review of patients with SCLE carried out at Odene University Hospital, Denmark. They identified 727 medical records with an *International Statistical Classification of Diseases and Related Health Problems*, tenth revision (ICD-10) diagnosis code of lupus erythematosus, 429 of which had confirmed cutaneous lupus erythematosus. In total, 24 patients with 30 episodes of PPI-induced SCLE were identified; 19 patients with 24 episodes were identified for the first time \[[@CR7]\], and the rest were identified earlier in clinical case reports \[[@CR8]\]. The incubation period was in the range of 1 week to 3.5 years (mean 8 months) and the resolution period was in the range of 4 weeks to 8 months (mean 3 months) after PPI discontinuation. Antinuclear antibodies, positive anti-Ro/SSA antibodies, positive anti-La/SSB antibodies, and anti-histone antibodies were found in 61, 73, 33, and 8 % of tested patients at the time of rash, respectively. Furthermore, in this cohort, two patients in whom PPIs were not discontinued had active SCLE up to their death.

### Case--Control Study {#Sec11}

We only identified one case--control study that evaluated the association between exposure to suspected drugs and subsequent diagnosis of SCLE \[[@CR2]\]. The study was a population-based matched case--control study in which 234 cases of SCLE in Sweden (2006--2009) derived from the National Patient Register were identified. The control group was matched on a 1:10 ratio (*n* = 2311) for sex, age, and country of residence. Of the 234 cases, 66 were identified as being associated with antithrombotics, followed by PPIs (*n* = 65), non-steroidal anti-inflammatory drugs (NSAIDs) (*n* = 51), and beta-blockers (*n* = 50). Among these drug groups, the odds ratios (ORs) were significant for PPIs (OR 2.9; 95 % CI 2.0--4.0), antithrombotics (OR 2.2; 95 % CI 1.5--3.2), and NSAIDs (OR 1.6; 95 % CI 1.1--2.2).

Discussion {#Sec12}
==========

Limitations of Analysis {#Sec13}
-----------------------

FAERS provides a passive pharmacovigilance risk signal and indicates associations. However, there is no certainty that the reported event (adverse event) was actually induced or caused by the drug product. Although the disproportionality analysis quantifies the signal to provide a picture of the drug-related risk, it in itself is generally insufficient to prove a causal relationship. The analysis, coupled with multiple sources of data such as clinical case reports and case--control studies, can be helpful in inferring the causal relationship and recommending and modifying clinical practice guidelines. Regulatory actions in response to emerging drug safety concerns often depend on an accurate assessment of risks using multiple data sources as well as consideration of overall benefits and risks of the agent \[[@CR9]\]. Therefore, this study should be placed in context with other such sources.

Further, FDA does not receive reports for every adverse event or medication error that occurs with a product. Identical or similar reports may be submitted by a healthcare professional and the patient or lawyer. Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event. Therefore, FAERS data cannot be used to calculate the incidence of an adverse event or medication error within a population \[[@CR4]\]. Well designed, randomized, prospective, large-scale, and long-term clinical trials are the best way to assess the relationship between an adverse event and a drug. On the other hand, while post-marketing vigilance such as FAERS has a limited ability to establish causal relationships, it does have advantages in terms of being able to identify signals in real-world situations with multi-drug regimens, reactivations of adverse events after cessation of therapy, and global differences in the occurrence of adverse events.

General Discussion {#Sec14}
------------------

Over the past decade, an increasing number of drugs in different classes have been implicated as triggers for drug-induced SCLE. Antihypertensives (including calcium channel blockers, diuretics, beta-blockers, and ACEIs), antifungals, chemotherapeutics, antihistamines, immunomodulators, antiepileptics, statins, NSAIDs, hormone-altering drugs, and ultraviolet therapy have all been reported as inducing SCLE. One possibility is that many drugs trigger SCLE by inducing a photosensitive state. Such a state might then nonspecifically induce SCLE skin lesions via an isomorphic response (Köbner response) in an individual who is immunogenetically predisposed to developing SCLE \[[@CR10]\].

In our analysis, 120 of the 220 SCLE cases reported in FAERS during the 2-year study period were associated with PPIs. The passive pharmacovigilance data indicated that PPIs were statistically significantly associated with lupus. However, it is possible that this is not a side effect of PPI but that a downstream mechanism is causing these symptoms. To explore this further, we compared PPIs and H2 receptor antagonists, an alternative to PPIs. PPIs work by inhibiting the K+/H+ ATPase pump in the lining of the gastric parietal cells. This reduces acid secretion because the hydrogen ions are unable to be transported to the gastric surface. H2 receptor antagonists work in a similar manner and have the same end effect: inhibition of the proton pump. However, H2 receptor antagonist drugs initially block the histamine channel. This channel downregulates the proton pump via the vagus nerve. Since H2 receptors also statistically significantly cause this phenomenon, it is likely that the proton pump induces SCLE instead of SCLE being a direct side effect of PPIs.

The statistically significant findings from our analysis of FAERS signals indicate the signal generated by FAERS is not false positive and that the SCLE is induced by PPIs. This cause--effect relationship is reinforced by the recurrence of SCLE upon re-challenge with the PPI in all nine longitudinally followed FAERS cases. Similarly, in the published clinical case reports where cessation of PPI treatment resulted in remission, a re-challenge again resulted in SCLE. PPI re-challenge caused SCLE to re-emerge with a shorter incubation period, reinforcing the relationship and indicating that an earlier episode of SCLE predisposes the patient to subsequent SCLE flare-ups.

At the Pharmacovigilance Risk Assessment Committee meeting in July 2015, the European Medicines Agency (EMA) issued a warning that SCLE is likely to be a class effect for PPIs \[[@CR11]\]. The warning further states that SCLE after previous treatment with a PPI may increase the risk of SCLE with other PPIs. In September 2015, the UK Medicines and Healthcare products Regulatory Agency (MHRA) \[[@CR12]\] stated that PPIs are associated with very infrequent cases of SCLE. These reports by the EMA and MHRA were based on the global safety databases of Takeda, Janssen/Eisai, and AstraZeneca, as well as comments received from marketing authorization holders. The FDA-approved PPI labels do not mention the adverse effect at all. The FDA should consider adding SCLE as an adverse event to PPI prescription labels. This can be supplemented with a Medication Guide for patients, containing adverse event warnings and describing alternatives to PPIs.

Clinical Practice Guidelines and Recommendations {#Sec15}
------------------------------------------------

Risk factors for developing SCLE include being a woman of child-bearing age, periods of female hormone changes, previous drug allergies or previous SCLE episodes, sun-reactive skin, exposure to ultraviolet radiation, and family history. When prescribing PPIs, especially to at-risk patients, the prescriber or the healthcare provider should ensure the patient is aware of the possibility of skin rash and SCLE and the associated symptoms. Patients should be advised to take protective measures against sun exposure, especially for bare skin. Non-allergic sunscreens or antioxidants may be applied to the skin if sun exposure cannot be avoided. If lesions occur, especially in sun-exposed areas of the skin, and if they are accompanied by arthralgia, the patient should seek medical help promptly. If the healthcare professional suspects SCLE and the patient is receiving any PPIs, the PPI should be discontinued immediately. The patient should be medically followed to observe remission of SCLE symptoms. If warranted, the patient can be treated with hydroxychloroquine, topical steroids, topical tacrolimus, and prednisolone \[[@CR10]\]. For acid reflux treatment, the patient may start one of the following: alginate and bicarbonate sodium \[[@CR13]\], magnesium carbonate, magnesium trisilicate, and magnesium hydroxide/milk of magnesia \[[@CR14]\]. PPIs should not be restarted, even if acid reflux symptoms do not subside, as they may induce a relapse of SCLE. H2 receptor antagonists may be initiated under medical supervision and the patient followed-up for any SCLE relapse. If neither of these therapies alleviates the symptoms, nissen fundoplication is also an option to consider. Regulatory bodies such as FDA should incorporate the drug-induced adverse reaction of SCLE in prescription labels of PPIs, especially for at-risk populations.

Conclusion {#Sec16}
==========

Analysis of passive pharmacovigilance data confirms a statistically significant association between SCLE and PPIs. SCLE can be induced by PPIs, and patients and prescribers should be made aware of the association between the two. An increased awareness among prescribers and patients can lead to withdrawal of the offending PPI and subsequent remission of the lupus erythematosus, decreasing the morbidity of the patients.
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